IL6 and COVID-19: While the plasma levels of all three cytokines are highly elevated in acute COVID-19,37,74,75 IL-6 in particular represents a key inflammatory driver of SARS-CoV-2-dependent immune pathogenesis as highlighted by its suitability as marker for severity and survival of COVID-1976,77 and the benefit of IL-6-directed treatment in hospitalized patients when combined with corticosteroids as found by the REMAP-CAP78 and RECOVERY79 trials.